Clinical Trial

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2023-02-24; most recent amendment 2025-08-15.
Status change: Not Yet Recruiting → Recruiting 2023-06-19
Trial Details
NCT Number NCT05744687
Lead Sponsor Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Locally Advanced or Metastatic Breast Cancer
Enrollment 374 participants
Start Date 2023-04-24
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-17